Open access · CC-BY
via OpenAlex
Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia
Annals of Geriatric Medicine and Research · 2019 · ▲ 171 citations
Abstract
Sarcopenia, the loss of skeletal muscle mass and function with age, was first recognized as a disease in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) (M62.84) and has recently attracted attention as aged populations increase. However, the diagnostic criteria for sarcopenia remain controversial and there are as yet no US Food and Drug Administration-approved medications for sarcopenia. Given that both intrinsic and extrinsic factors contribute to sarcopenia onset and development, understanding the mechanism of sarcopenia is important for the development of therapeutic strategies. In this review, we described a variety of drugs for sarcopenia under investigation, including myostatin/ActR2 signaling inhibitors, exercise mimetics, anabolic hormones, and natural compounds. However, the combination of non-drug therapies with exercise and nutritional supplements are also needed as more easily accessible intervention strategies against sarcopenia rather than pharmacological treatments alone. Many approaches to develop therapeutic methods to overcome sarcopenia may lead to healthy aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.4235/agmr.19.0028
- Canonical
- link ↗
- Fetched
- 2026-09-21 MST
Cite this
APA
Kwak, J.Y., & Kwon, K. (2019). Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia. <em>Annals of Geriatric Medicine and Research</em>. https://doi.org/10.4235/agmr.19.0028
Vancouver
Kwak JY, Kwon K. Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia. Annals of Geriatric Medicine and Research. 2019. doi:10.4235/agmr.19.0028.
BibTeX
@article{ju2019Pharma,
title = {Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia},
author = {Ju Yeon Kwak and Ki‐Sun Kwon},
journal = {Annals of Geriatric Medicine and Research},
year = {2019},
doi = {10.4235/agmr.19.0028},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Proteomes 2022
Open access · CC-BY
Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia
Foods 2020
Open access · CC-BY
Apitherapy for Age-Related Skeletal Muscle Dysfunction (Sarcopenia): A Review on the Effects of Royal Jelly, Propolis, and Bee Pollen
Inflammation and regeneration 2026
Open access · OA
Natural killer cells: gatekeepers of healthy aging in longevity medicine.
Circulation 2023
Open access · CC-BY
Sarcopenia and Cardiovascular Diseases
Journal of Cachexia Sarcopenia and Muscle 2022
Open access · CC-BY
Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control
Cell Metabolism 2025
Open access · CC-BY